Conflict of Interest / Disclosure Policy

Whenever there is the potential for conflict of interest, details of funding, sponsorship, financial involvement and possible conflicts of interest will be prominently and fully disclosed.

General Disclosures:

Dr. C. Michael Gibson, M.S., M.D., Editor-In-Chief

Currently there is no direct funding for the development and maintenance of this webpage. Some CME programs are sponsored as indicated.  We are currently seeking assistance from any interested parties.  The site is supported by volunteer efforts from Susan J. Marble and Dr. C. Michael Gibson.  Dr. Gibson is founder and director of PERFUSE (Percutaneous/Pharmacologic Endoluminal Revascularization For Unstable Syndromes & its Evaluation) and the TIMI Angiographic Core Laboraotories (non- profit entities) with over a decade of experience in cardiovascular research.  Over the years PERFUSE / TIMI  has received the research grant support from the following entities:

Government Agencies

The NIH  (HARP, PEARL); HCFA (Medicare CABG project)

Industry (in alphabetical order)

Acusphere; Astra (STEP AMI); Aventis / RPR (TIMI 11, ENTIRE); Bard (Perfusion balloon trial); Boston Scientific (Wallgraft studies); Bristol Meyer Squibb (HARP, CLARITY); British Biotech; Ciba Geigy (TIMI 9); Millenium Pharmaceuticals / COR Therapeutics (ESPRIT / TITAN / ADVANCE MI / PROTECT/Early ACS); Corgentech (PREVENT 4); DVI Guidant (Intermediate vessel atherectomy trial); Eli Lilly / Centocor (TIMI 14, SPEED); Genentech (TIMI 10, TIMI 12, LIMIT, VIVA); Merck (RESTORE, TACTICS, TARGET); Park Davis (AVERT); Percusurge, Point Biomedical; Smith Kline Beecham (TIMI 4); Sonus (Echogen trial); St Judes (Evaluation of Proximal Anastomotic Device); TIMI 3 Systems (the PLUS trial).

This website is owned and managed by PIXCELLA  LLC.